San Diego, CA — September 15, 2026 — Axiom Biosciences, a clinical-stage biotechnology company developing next-generation regenerative therapies and targeted biologics, today announced a strategic partnership with GeneFab, a cell and gene therapy…
Sanofi and CHEPLAPHARM, a European market leader in established branded medicines, today announced their intention to enter into a strategic partnership under which CHEPLAPHARM will acquire 20 established medicines and three global manufacturing…
AstraZeneca, Boehringer Ingelheim, and Sanofi are some of the other companies that have struck agreements with Owkin.
The agreement extends manufacturing commitments through 2033 and pushes Samsung Biologics' cumulative contract value above $21.9 billion.
GSK gains rights outside Greater China to develop HMPL-A830 for KRAS-altered tumors.
The collaboration pairs Exegenesis Bio's EMC181 muscle-tropic AAV capsid with Modalis' CRISPR-GNDM platform to advance MDL-201.
The 21,000-square-foot facility will train students for careers in aseptic and sterile pharmaceutical manufacturing.
Currently in preclinical development, OC-3 is a potentially best-in-class treatment for cancers defective in DNA homologous recombination repair.
Collaboration aims to support manufacturing readiness for next-generation bioprocessing technologies.
Funding comes from the Eurostars Program, national agencies in Sweden and Austria, and the European Union through Horizon Europe.
Expanded agreement gives Transgene access to scalable production technology.
GSK gains rights outside Greater China to develop HMPL-A830 for KRAS-altered tumors.
Stay informed with the latest pharmaceutical, biotech and medical device industry news. Updated daily by our editorial team.
